Comparison of the biomarkers for targeted therapies in primary extra‐mammary and mammary Paget's disease

Primary Extra‐mammary Paget's disease (EMPD) is a very rare cutaneous adenocarcinoma affecting anogenital or axillary regions. It is characterized by a prolonged course with recurrences and eventually distant metastatic spread for which no specific therapy is known.

[1]  A. Wolff,et al.  TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer , 2019, Clinical Cancer Research.

[2]  C. Stafford,et al.  High Risk of Proximal and Local Neoplasms in 2206 Patients With Anogenital Extramammary Paget's Disease. , 2019, Diseases of the colon and rectum.

[3]  P. Stafford,et al.  Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling , 2019, Cancer medicine.

[4]  R. Kurzrock,et al.  Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients , 2019, International journal of cancer.

[5]  S. Lippman,et al.  Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy , 2019, Cancer Immunology Research.

[6]  M. Franchi,et al.  The vulvar immunohistochemical panel (VIP) project: molecular profiles of vulvar Paget’s disease , 2019, Journal of Cancer Research and Clinical Oncology.

[7]  F. Couch,et al.  Hereditary Cancer Syndromes-A Primer on Diagnosis and Management, Part 2: Gastrointestinal Cancer Syndromes. , 2019, Mayo Clinic proceedings.

[8]  J. Wargo,et al.  Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy , 2019, Cancers.

[9]  C. Lebbé,et al.  Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas , 2019, Cancer Immunology, Immunotherapy.

[10]  K. Kinoshita,et al.  Identification of genetic alterations in extramammary Paget disease using whole exome analysis. , 2019, Journal of dermatological science.

[11]  M. Franchi,et al.  Reviewing vulvar Paget’s disease molecular bases. Looking forward to personalized target therapies: a matter of CHANGE , 2019, International Journal of Gynecologic Cancer.

[12]  Ralitsa R. Madsen,et al.  Cancer-Associated PIK3CA Mutations in Overgrowth Disorders , 2018, Trends in molecular medicine.

[13]  J. Swensen,et al.  Molecular characterization of cancers with NTRK gene fusions , 2018, Modern Pathology.

[14]  Kongming Wu,et al.  Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors , 2018, Molecular cancer.

[15]  M. Beckmann,et al.  Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization. , 2018, Archives of pathology & laboratory medicine.

[16]  M. Péoc'h,et al.  Expression of CD3, PD-L1 and CTLA-4 in mammary and extra-mammary Paget disease , 2018, Cancer Immunology, Immunotherapy.

[17]  J. Swensen,et al.  Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. , 2018, European journal of cancer.

[18]  M. Furue,et al.  The diagnosis and management of extramammary Paget’s disease , 2018, Expert review of anticancer therapy.

[19]  T. Funakoshi,et al.  Metastatic Extramammary Paget’s Disease: Pathogenesis and Novel Therapeutic Approach , 2018, Front. Oncol..

[20]  J. Marshall,et al.  Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients , 2018, Cancer medicine.

[21]  T. Koizumi,et al.  Successful and long-term response to trastuzumab plus paclitaxel combination therapy in human epidermal growth factor receptor 2-positive extramammary Paget's disease: A case report and review of the literature , 2017, Molecular and clinical oncology.

[22]  Guohong Zhang,et al.  Mammary and Extramammary Paget's Disease Presented Different Expression Pattern of Steroid Hormone Receptors , 2017, BioMed research international.

[23]  G. Heestand,et al.  Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients , 2017, European journal of cancer.

[24]  Melissa B. Davis,et al.  AR negative triple negative or “quadruple negative” breast cancers in African American women have an enriched basal and immune signature , 2017, PloS one.

[25]  Jinhua Xu,et al.  Genetic Analysis of Mismatch Repair Genes Alterations in Extramammary Paget Disease , 2016, The American journal of surgical pathology.

[26]  Y. Fujisawa,et al.  A proposal for a TNM staging system for extramammary Paget disease: Retrospective analysis of 301 patients with invasive primary tumors. , 2016, Journal of dermatological science.

[27]  Gerben Duns,et al.  SETD2: an epigenetic modifier with tumor suppressor functionality , 2016, Oncotarget.

[28]  Y. Fujisawa,et al.  The role of sentinel lymph node biopsy in the management of invasive extramammary Paget's disease: Multi-center, retrospective study of 151 patients. , 2015, Journal of dermatological science.

[29]  Qiang Ding,et al.  PI3Kβ Inhibitor TGX221 Selectively Inhibits Renal Cell Carcinoma Cells with Both VHL and SETD2 mutations and Links Multiple Pathways , 2015, Scientific Reports.

[30]  S. Millis,et al.  Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. , 2015, Clinical genitourinary cancer.

[31]  S. Millis,et al.  Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature , 2015, Case reports in oncological medicine.

[32]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[33]  Z. Keidar,et al.  Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F. , 2014, The oncologist.

[34]  David T. W. Jones,et al.  Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas , 2013, Acta Neuropathologica.

[35]  M. Guan,et al.  Oncogenic mutations in extramammary Paget's disease and their clinical relevance , 2013, International journal of cancer.

[36]  M. Guan,et al.  Correlation of DLC1 gene methylation with oncogenic PIK3CA mutations in extramammary Paget's disease , 2012, Modern Pathology.

[37]  O. Dorigo,et al.  Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease. , 2012, Gynecologic oncology.

[38]  H. Matsue,et al.  Dramatic Clinical Response of Relapsed Metastatic Extramammary Paget's Disease to Trastuzumab Monotherapy , 2012, Case reports in dermatological medicine.

[39]  N. Shibagaki,et al.  A Case of Metastatic Extramammary Paget's Disease Responding to Trastuzumab plus Paclitaxel Combination Therapy , 2011, Case Reports in Dermatology.

[40]  Yves Pommier,et al.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. , 2010, Chemistry & biology.

[41]  M. Hide,et al.  Metastatic extramammary Paget’s disease treated with paclitaxel and trastuzumab combination chemotherapy , 2009, The Journal of dermatology.

[42]  J. Rao,et al.  HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review. , 2008, Gynecologic oncology.

[43]  T. Saida,et al.  Estrogen-Receptor-Alpha-Positive Extramammary Paget’s Disease Treated with Hormonal Therapy , 2006, Dermatology.

[44]  A. Utani,et al.  Androgen‐deprivation regimen for multiple bone metastases of extramammary Paget disease , 2005, The British journal of dermatology.

[45]  L. Horn,et al.  Androgen receptors are frequently expressed in mammary and extramammary Paget's disease , 2005, Modern Pathology.

[46]  Z. Gatalica,et al.  Extramammary Paget disease is characterized by the consistent lack of estrogen and progesterone receptors but frequently expresses androgen receptor. , 2000, American journal of clinical pathology.

[47]  P. Clement,et al.  Prognostic factors in Paget's disease of the vulva: a study of 21 cases. , 1999, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[48]  B. Lloveras,et al.  Estrogen receptors in skin appendage tumors and extramammary Paget's disease. , 1991, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.